GSK plc
GSK
$51.84
-$1.12-2.12%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -70.13% | 12.29% | 59.54% | 3,696.29% | 30.27% |
| Total Depreciation and Amortization | -64.30% | -40.94% | -423.43% | -19.59% | 2.58% |
| Total Amortization of Deferred Charges | -- | -- | 8.28% | -- | -- |
| Total Other Non-Cash Items | 36.96% | 104.70% | -14.02% | 89.97% | 1,492.29% |
| Change in Net Operating Assets | 153.82% | -44.15% | 188.24% | -130.51% | -76.66% |
| Cash from Operations | 27.18% | 4.62% | 1.58% | 6.89% | 99.42% |
| Capital Expenditure | -26.97% | -11.55% | -9.39% | -5.66% | 10.24% |
| Sale of Property, Plant, and Equipment | -40.54% | 2,734.51% | -77.87% | 418.10% | 164.73% |
| Cash Acquisitions | -22,460.55% | -84.08% | 31.30% | -22,178.29% | 90.37% |
| Divestitures | 153.09% | 25,820.50% | 120.77% | 134.54% | -323.57% |
| Other Investing Activities | 158.94% | 13.96% | 39.27% | 9.70% | -132.72% |
| Cash from Investing | -25.10% | -34.53% | 13.41% | -117.02% | -185.95% |
| Total Debt Issued | -57.67% | -42.13% | -58.84% | -- | -- |
| Total Debt Repaid | 39.06% | 66.20% | 93.15% | 89.74% | -163.76% |
| Issuance of Common Stock | -50.00% | -33.33% | -- | -100.00% | 100.00% |
| Repurchase of Common Stock | 45.10% | -31.98% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -9.82% | -10.30% | -9.62% | -10.05% | -6.54% |
| Other Financing Activities | -86.96% | 166.67% | -3.35% | -724.00% | 31.75% |
| Cash from Financing | 10.22% | -66.72% | -5.58% | -9.89% | -58.57% |
| Foreign Exchange rate Adjustments | 73.32% | 119.09% | -708.27% | 279.81% | -244.15% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.34% | -106.31% | 24.07% | -492.92% | -437.33% |